Harmonex Neuroscience Research Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$2,137	2
2020	Research	$11,714	26
2019	Research	$105,979	11

Breakdown

Who paid Research payments · program years 2019–2021

Sunovion Pharmaceuticals Inc. $88,238 2 payments
Shire North American Group Inc $17,191 8 payments
Takeda Pharmaceuticals U.S.A., Inc. $10,464 23 payments
H. Lundbeck A S $2,137 2 payments
Pfizer Inc. $1,800 4 payments

Studies the money was for Research payments · program years 2019–2021

Pediatric Open-Label Extension Study $88,238 2 payments
A Phase 3, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled, Fixed-Dose Safety and Efficacy Study of Spd489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-Deficithyperactivity Disorder $6,896 2 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficithyperactivity Disorder Adhd $6,553 1 payment
A Phase 3, Open-Label, Multicenter, 12-Month Safety and Tolerability Study of Spd489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-Deficit / Hyperactivity Disorder $4,456 1 payment
A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $4,425 20 payments
A Phase 3, Open-Label, Multicenter, 12-Month Safety and Tolerability Study of Spd489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-Deficit Hyperactivity Disorder $3,742 5 payments
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) $2,137 2 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (Adhd) $1,584 2 payments
Sprites Sertraline Pediatric Registry for the Evaluation of Safety A Noninterventional Longitudinal Cohort Study to Evaluate the Effects of Longterm Sertraline Treatment in Children and Adolescents $1,300 3 payments
Phase 1 Openlabel Randomized Singledose 2Treatment 2Period Crossover Bioequivalence Study Comparing Sertraline Hydrochloride 50 MG Filmcoated Tablets to Sertraline Hydrochloride 50 MG Hard Capsules Under Fasted Conditions $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.